

HALOZYME THERAPEUTICS INC

Form 4

July 02, 2007

FORM 4**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB
Number: 3235-0287
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
Lim Jonathan E

(Last) (First) (Middle)

C/O HALOZYME
THERAPEUTICS, INC., 11588
SORRENTO VALLEY ROAD,
SUITE 17

(Street)

SAN DIEGO, CA 92121

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading
Symbol
HALOZYME THERAPEUTICS
INC [HALO]

3. Date of Earliest Transaction
(Month/Day/Year)
06/29/2007

4. If Amendment, Date Original
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

☒ Director ☐ 10% Owner
☒ Officer (give title below) ☐ Other (specify below)
President, CEO

6. Individual or Joint/Group Filing(Check
Applicable Line)

☒ Form filed by One Reporting Person
☐ Form filed by More than One Reporting
Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/29/2007		M ⁽¹⁾		25,000	A	\$ 0.39 698,310
Common Stock	06/29/2007		S ⁽¹⁾		100	D	\$ 9.16 698,210
Common Stock	06/29/2007		S ⁽¹⁾		100	D	\$ 9.17 698,110
Common Stock	06/29/2007		S ⁽¹⁾		100	D	\$ 9.18 698,010

Edgar Filing: HALOZYME THERAPEUTICS INC - Form 4

Common Stock	06/29/2007	<u>S⁽¹⁾</u>	200	D	\$ 9.23	697,810	D
Common Stock	06/29/2007	<u>S⁽¹⁾</u>	100	D	\$ 9.24	697,710	D
Common Stock	06/29/2007	<u>S⁽¹⁾</u>	300	D	\$ 9.26	697,410	D
Common Stock	06/29/2007	<u>S⁽¹⁾</u>	200	D	\$ 9.27	697,210	D
Common Stock	06/29/2007	<u>S⁽¹⁾</u>	100	D	\$ 9.28	697,110	D
Common Stock	06/29/2007	<u>S⁽¹⁾</u>	800	D	\$ 9.3	696,310	D
Common Stock	06/29/2007	<u>S⁽¹⁾</u>	600	D	\$ 9.32	695,710	D
Common Stock	06/29/2007	<u>S⁽¹⁾</u>	900	D	\$ 9.33	694,810	D
Common Stock	06/29/2007	<u>S⁽¹⁾</u>	1,100	D	\$ 9.36	693,710	D
Common Stock	06/29/2007	<u>S⁽¹⁾</u>	600	D	\$ 9.37	693,110	D
Common Stock	06/29/2007	<u>S⁽¹⁾</u>	600	D	\$ 9.38	692,510	D
Common Stock	06/29/2007	<u>S⁽¹⁾</u>	300	D	\$ 9.385	692,210	D
Common Stock	06/29/2007	<u>S⁽¹⁾</u>	1,960	D	\$ 9.39	690,250	D
Common Stock	06/29/2007	<u>S⁽¹⁾</u>	286	D	\$ 9.4	689,964	D
Common Stock	06/29/2007	<u>S⁽¹⁾</u>	681	D	\$ 9.41	689,283	D
Common Stock	06/29/2007	<u>S⁽¹⁾</u>	400	D	\$ 9.48	688,883	D
Common Stock	06/29/2007	<u>S⁽¹⁾</u>	100	D	\$ 9.49	688,783	D
Common Stock	06/29/2007	<u>S⁽¹⁾</u>	1,100	D	\$ 9.5	687,683	D
Common Stock	06/29/2007	<u>S⁽¹⁾</u>	100	D	\$ 9.505	687,583	D
Common Stock	06/29/2007	<u>S⁽¹⁾</u>	2,000	D	\$ 9.51	685,583	D
	06/29/2007	<u>S⁽¹⁾</u>	100	D		685,483	D

Edgar Filing: HALOZYME THERAPEUTICS INC - Form 4

Common Stock						\$ 9.515		
Common Stock	06/29/2007	S ⁽¹⁾	1,374	D	\$ 9.52	684,109	D	
Common Stock	06/29/2007	S ⁽¹⁾	500	D	\$ 9.53	683,609	D	
Common Stock	06/29/2007	S ⁽¹⁾	200	D	\$ 9.535	683,409	D	
Common Stock	06/29/2007	S ⁽¹⁾	700	D	\$ 9.54	682,709	D	
Common Stock	06/29/2007	S ⁽¹⁾	1,200	D	\$ 9.55	681,509	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)
				Code	V (A) (D)	Date Exercisable Expiration Date	Title Amount or Number of Shares
Options to Purchase Common Stock	\$ 0.39	06/29/2007		M ⁽¹⁾	25,000	11/11/2003 11/11/2013	Common Stock 25,000

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director 10% Owner Officer Other
Lim Jonathan E C/O HALOZYME THERAPEUTICS, INC. 11588 SORRENTO VALLEY ROAD, SUITE 17	X President, CEO

SAN DIEGO, CA 92121

Signatures

/s/ Jonathan E.
Lim

06/29/2007

__Signature of
Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Shares purchased and sold, as applicable, pursuant to 10b5-1 Plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.